title: Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm.
abstract: The motivational component of drug withdrawal may contribute to drug seeking and relapse through the negative reinforcement-related process; thus, it is important to understand the mechanisms that mediate affective withdrawal behaviors. The present study was undertaken to examine the calcium-dependent mechanism of negative motivational symptoms of nicotine and morphine withdrawal using the conditioned place aversion (CPA) paradigm. Rats were chronically treated with nicotine (1.168 mg/kg, free base, s.c., 11 days, three times daily) or morphine (10 mg/kg,s.c., 11 days, twice daily). Then, during conditioning, rats pre-treated with nicotine or morphine received a nicotinic receptor antagonist mecamylamine (3.5 mg/kg) or an opioid receptor antagonist naloxone (1 mg/kg) to precipitate withdrawal in their initially preferred compartment, or saline in their non-preferred compartment. Our results demonstrated that after three conditioning sessions, mecamylamine induced a clear place aversion in rats that had previously received nicotine injections, and naloxone induced a significant place aversion in rats that had previously received morphine injections. Further, the major findings showed that calcium channel antagonists, i.e., nimodipine, verapamil and flunarizine (5 and 10 mg/kg, i.p.), injected before the administration of mecamylamine or naloxone, attenuated nicotine or morphine place aversion. As an outcome, these findings support the hypothesis that similar calcium-dependent mechanisms are involved in aversive motivational component associated with nicotine a morphine withdrawal. We can suggest that calcium channel blockers have potential for alleviating nicotine and morphine addiction by selectively decreasing the incentive motivational properties of both drugs, and may be beneficial as smoking cessation or opioid dependence pharmacotherapies.
authors.affiliation: Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Budzynska
authors.forename: Piotr
authors.initials: P
authors.lastname: Polak
authors.forename: Grazyna
authors.initials: G
authors.lastname: Biala
mesh_terms: D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005444:Flunarizine / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009042:Motivation / Q000187:drug effects*; D009538:Nicotine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D009553:Nimodipine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013375:Substance Withdrawal Syndrome / Q000523:psychology; D014700:Verapamil / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D009553:Nimodipine; D009538:Nicotine; D009020:Morphine; D014700:Verapamil; D005444:Flunarizine